Prenetics, a Hong Kong-based DNA biotechnology company, raised $2.65M in seed funding.
The round was led by Danny Yeung, who has joined the company as its CEO and investor, with participation from international investors.
Based on advanced DNA technology developed at Stanford University and co-founded by Dr Lawrence Tzang, Chief Scientific Officer, Prenetics has officially launched today a new DNA based Non-Invasive Prenatal Test (NIPT) for the early detection of fetal health problems. The Prenetics V® test provides comprehensive testing as early as the tenth week of pregnancy, with 99.9% accuracy and results in just 5-7 days.
The company also operates an ISO-accredited and World Health Organization-certified diagnostics laboratory in Hong Kong.